OverviewSuggest Edit

Ascentage Pharma (亚盛医药) is a clinical-stage biopharmaceutical company developing small molecule therapies for cancers, hepatitis B, and age-related diseases. Its expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers.
TypePublic
Founded2009
HQSuzhou Shi, CN
Websiteascentagepharma.com

Latest Updates

Employees (est.) (Jul 2021)433
Share Price (Nov 2021)$29.3(+6%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ascentage Pharma

Yang Dajun

Yang Dajun

Chairman of the Board, Executive Director and Chief Executive Officer
Guo Edward Ming

Guo Edward Ming

Co-Founder, President & Chief Operating Officer
Zhai Yifan

Zhai Yifan

Chief Medical Officer
Raymond Jeffrey Kmetz

Raymond Jeffrey Kmetz

Chief Business Officer
Thomas Joseph Knapp

Thomas Joseph Knapp

Senior Vice President, General Counsel
Wang Shaomeng

Wang Shaomeng

Co-Founder, Non-Executive Director, Chief Science Advisor
Show more

Ascentage Pharma Office Locations

Ascentage Pharma has offices in Suzhou Shi, Guangzhou Shi, Taizhou and Rockville
Suzhou Shi, CN (HQ)
building b7, 7th floor, 218 Xinghu St, Wuzhong Qu
Guangzhou Shi, CN
2706, 403 Huanshi E Rd, Huan Shi Dong Lu Yan Xian, Yuexiu Qu
Taizhou, CN
Hailing District
Rockville, MD, US
800 King Farm Blvd #300
Show all (6)

Ascentage Pharma Financials and Metrics

Ascentage Pharma Revenue

Market capitalization (10-Nov-2021)

7.2b

Closing stock price (10-Nov-2021)

29.3
Ascentage Pharma's current market capitalization is $7.2 b.
Show all financial metrics

Ascentage Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Ascentage Pharma Online and Social Media Presence

Embed Graph

Ascentage Pharma News and Updates

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer

SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced a clinical trial...

Ascentage Pharma Announces 2021 Interim Results Highlighting the Potential of Its Core Drug Candidates and Major Breakthroughs in Strategic Collaborations

SUZHOU, China, and ROCKVILLE, Md., Aug. 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2021 interim results and released an...

Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax

SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a...

ASCO 2021 | Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract...

Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of...

Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 25, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed...
Show more

Ascentage Pharma Blogs

Ascentage Pharma and Innovent Biologics Announce Approval for China’s First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, and ROCKVILLE, MD, Nov. 30, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceu…

Ascentage Appoints Mr. Yiqing Chen as Chief Financial Officer

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the appointment of Mr. Yiqing Chen as Chief Financial Officer (CFO), reporting directly to Dr. Dajun Yang, Chairman a…

Ascentage Pharma’s Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, and ROCKVILLE, MD., Nov.22, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC) has granted the company’s novel d…

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on six studies of the company’s three drug candidate…

ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting

UZHOU, China, and ROCKVILLE, MD., Nov. 5, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on three clinical trials of the company’s novel drug …

JMC Publishes Study Showing Potential of EED Inhibitor EEDi-5273

Ascentage Pharma (6855.HK) today announced that a research team led by Prof. Shaomeng Wang, Ph.D., Co-Founder and Chief Scientific Advisor of Ascentage Pharma, and Warner-Lambert/Parke-Davis Professor in Medicine, Professor of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Mi…
Show more

Ascentage Pharma Frequently Asked Questions

  • When was Ascentage Pharma founded?

    Ascentage Pharma was founded in 2009.

  • Who are Ascentage Pharma key executives?

    Ascentage Pharma's key executives are Yang Dajun, Guo Edward Ming and Zhai Yifan.

  • How many employees does Ascentage Pharma have?

    Ascentage Pharma has 433 employees.

  • Who are Ascentage Pharma competitors?

    Competitors of Ascentage Pharma include Italfarmaco, EUSA Pharma and Chugai Pharmaceutical.

  • Where is Ascentage Pharma headquarters?

    Ascentage Pharma headquarters is located at building b7, 7th floor, 218 Xinghu St, Wuzhong Qu, Suzhou Shi.

  • Where are Ascentage Pharma offices?

    Ascentage Pharma has offices in Suzhou Shi, Guangzhou Shi, Taizhou and Rockville.

  • How many offices does Ascentage Pharma have?

    Ascentage Pharma has 6 offices.